Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of chemically diverse drug-like small molecule compounds
Subscribe to our email newsletter
Nuevolution has reported the execution of a worldwide technology cross-licensing agreement with GlaxoSmithKline (GSK).
Reportedly, the agreement relates to a number of patented technologies for rapid synthesis and DNA-tagging of hundreds of millions of chemically diverse drug-like small molecule compounds and their efficient screening, facilitating the identification of potent drug leads.
Under the terms of the cross-licensing agreement, GSK will obtain a non-exclusive license under technology patents of Nuevolution, whereas Nuevolution will obtain a one time license fee and a non-exclusive license under technology patents of GSK.
Alex Gouliaev, CEO of Nuevolution, said: Our innovative technologies allow small molecule hit and lead discovery at an unprecedented scale. This agreement secures both companies the rights to operate these powerful technologies to their fullest extent.